Acacia Subsidiary Acquires Patents Relating to Vascular Device Technology

  Acacia Subsidiary Acquires Patents Relating to Vascular Device Technology

Business Wire

NEWPORT BEACH, Calif. -- January 31, 2013

Acacia Research Corporation (Nasdaq: ACTG) announced today that a subsidiary
has acquired patents relating to vascular device technology.

“Acacia and its subsidiaries continue to increase the number of patent
portfolios they control in the medical device and diagnostics sectors,”
commented Paul Ryan, CEO.


Acacia Research Corporation’s subsidiaries partner with inventors and patent
owners, license the patents to corporate users, and share the revenue. Acacia
Research Corporation’s subsidiaries control 250 patent portfolios, covering
technologies used in a wide variety of industries.

Information about Acacia Research Corporation and its subsidiaries is
available at and

Safe Harbor Statement under the Private Securities Litigation Reform Act of

This news release contains forward-looking statements within the meaning of
the “safe harbor” provisions of the Private Securities Litigation Reform Act
of 1995. These statements including those of Paul Ryan relating to the number
of patent portfolios that are controlled, are based upon our current
expectations and speak only as of the date hereof. The ability of Acacia and
its subsidiaries to continue increasing the number of controlled patent
portfolios in the medical device and diagnostics sectors, and our actual
results may differ materially and adversely from those expressed in any
forward-looking statements as a result of various factors and uncertainties,
including the ability to identify and secure patent partners in the medical
sector, the ability to successfully develop licensing programs and attract new
business, recent economic slowdown affecting technology companies, rapid
technological change in relevant markets, changes in demand for current and
future intellectual property rights, legislative, regulatory and competitive
developments addressing licensing and enforcement of patents and/or
intellectual property in general, and general economic conditions. Our Annual
Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q,
recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss
some of the important risk factors that may affect our business, results of
operations and financial condition. We undertake no obligation to revise or
update publicly any forward-looking statements for any reason.


Acacia Research Corporation
Rob Stewart
Investor Relations
Tel (949) 480-8300
Fax (949) 480-8301
Media Contact:
SpecOps Communications
Adam Handelsman
President & Founder
(212) 518-7721
Press spacebar to pause and continue. Press esc to stop.